ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer

ClinicalTrials.gov ID: NCT02508077

Public ClinicalTrials.gov record NCT02508077. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 16, 2026, 5:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Prospective Study of FOLFIRI Plus Panitumumab in Extended RAS Wild Type and BRAF Wild Type Metastatic Colorectal Cancer With Acquired Resistance to Prior Cetuximab (or Panitumumab) Plus Irinotecan-Based Therapy and Who Failed at Least One Subsequent Non-anti-EGFR Containing Regimen

Study identification

NCT ID
NCT02508077
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
City of Hope Medical Center
Other
Enrollment
1 participant

Conditions and interventions

Interventions

  • Fluorouracil Drug
  • Irinotecan Hydrochloride Drug
  • Laboratory Biomarker Analysis Other
  • Leucovorin Calcium Drug
  • Panitumumab Biological

Drug · Other · Biological

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 15, 2016
Primary completion
Sep 12, 2017
Completion
Sep 12, 2017
Last update posted
Aug 15, 2018

2016 – 2017

United States locations

U.S. sites
4
U.S. states
1
U.S. cities
4
Facility City State ZIP Site status
City of Hope Medical Center Duarte California 91010
City of Hope Antelope Valley Lancaster California 93534
City of Hope Rancho Cucamonga Rancho Cucamonga California 91730
South Pasadena Cancer Center South Pasadena California 91030

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02508077, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 15, 2018 · Synced May 16, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02508077 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →